GRX2672 / Guardian Therap, PinotBio - LARVOL DELTA

Targeting LRRC15 with an aptamer-drug conjugate achieves complete tumor growth inhibition (AACR 2026) - "The resulting ApDC, GRX2672, selectively kills LRRC15-positive cells in vitro and achieves complete tumor growth inhibition in vivo without observed toxicity. These findings support the potential of LRRC15-targeted ApDCs as an emerging therapeutic strategy to improve outcomes for patients with LRRC15-positive tumors."

Brain Cancer • Glioblastoma • Melanoma • Oncology • Sarcoma • Solid Tumor • LRRC1